Linnaeus Therapeutics key facts
as of Oct 2026- Developer of molecular therapeutics designed to treat cancer and skin pigmentation disorders.
- Linnaeus Therapeutics is valued at approximately $83.1M as of Oct 2026, set at its later-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $35.6M across 8 recorded rounds; the latest was Seed Round ($5.0M) in Feb 2026.
- Notable investors include Springboard Enterprises, Kairos Ventures, National Cancer Institute, National Institute for Allergy and Infectious Disease, Penn Center for Innovation — 8 tracked in total.
- Linnaeus Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently Mar 2026 ($4.8M sold to 25 investors).
- Status: Privately Held (backing).
Valued at $83.1M at its later-stage round, Apr 2026. Nothing has traded since.
- ·Watch Linnaeus Therapeutics: the Monday email on marks, rounds and moves
Linnaeus Therapeutics funding rounds
8 roundsLinnaeus Therapeutics valuation
Linnaeus Therapeutics was valued at $83.1 million at its later-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Linnaeus Therapeutics raised?
Linnaeus Therapeutics has raised $35.6 million across 8 recorded rounds since 2018. The largest was a $5.8 million early-stage round in Aug 2024; the most recent was a $5 million seed round in Feb 2026.
Linnaeus Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently in Mar 2026 ($4.8 million sold to 25 investors).
Linnaeus Therapeutics investors
8 investors are on record for Linnaeus Therapeutics, including Springboard Enterprises, Kairos Ventures, National Cancer Institute and National Institute for Allergy and Infectious Disease. The seed round in Feb 2026 drew 26 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Indapta Therapeutics ($90 million), Hyku Biosciences ($85 million) and Pangea Bio ($80 million).
About Linnaeus Therapeutics
Developer of molecular therapeutics designed to treat cancer and skin pigmentation disorders. The company's therapeutics utilize small-molecule agents to increase or decrease the amount of melanin pigment produced by skin cells, enabling medical practitioners to treat cancer and skin pigmentation disorders due to oncogenic mutations effectively.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Haddonfield, NJ, United States
- Founded
- 2016
- Employees
- 5
- Website
- linnaeustx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.